Datamonitor's Drug Repositioning Strategies

Datamonitor's Drug Repositioning Strategies

Gain an insight into how drugs have been, and are being repositioned

Drug repositioning is increasingly being seen as an attractive strategy for drug discovery, with its shorter timelines, lower costs, and reduced risk relative to conventional de novo drug discovery. Most innovative pharmaceutical companies lack the resources to reposition drugs effectively,and are looking outside, leading to the burgeoning of an industry dedicated to do just this.

The new Datamonitor report Drug Repositioning Strategies - Serendipity by design provides an overview of drug repositioning and the motivations driving it, in addition to the methods used by the key players. Several examples of drugs which have either been or are being repositioned are described.

Use this new report as a platform to:

• Understand what drug repositioning is, and why it is important.
• Become aware of who the key players in drug repositioning are and how they operate.

According to the report:

Despite increasing R&D investment, productivity has been declining, at a time when Big Pharma is contending with latestage pipeline failures and more rigorous drug approval procedures, in addition to external challenges in the form of generic competition and pricing pressures.

The cost savings, accelerated path to market, and lower risks that repositioning brings relative to traditional discovery are attractive to Big Pharma, which has thus far been filling pipeline gaps by inlicensing, a practice which has become more expensive as competition for candidates increases.

The companies involved in repositioning currently differ greatly in the methodologies used, in addition to their disease focus, however as the strategy gains traction, the industry is likely to undergo considerable consolidation.

Publisher :  Datamonitor
 
Product Types :

• Reports

Departments :

• Other Marketing Products

ORDER CLASS: DDRS
SOURCE CODE: EHCM